Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.

Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F.

Leukemia. 2019 Oct 14. doi: 10.1038/s41375-019-0589-3. [Epub ahead of print] No abstract available.

PMID:
31611624
2.

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy.

Ballo O, Stratmann J, Serve H, Steffen B, Finkelmeier F, Brandts C.

PLoS One. 2019 Sep 30;14(9):e0223013. doi: 10.1371/journal.pone.0223013. eCollection 2019.

3.

Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.

Stratmann J, van Kann E, Rummelt C, Koschade S, Röllig C, Lübbert M, Schaich M, Parmentier S, Sebastian M, Chromik J, Becker von Rose A, Ballo O, Steffen B, Serve H, Brandts C, Shaid S.

Leuk Res. 2019 Oct;85:106192. doi: 10.1016/j.leukres.2019.106192. Epub 2019 Aug 10.

PMID:
31445469
4.

Selective Autophagy in Normal and Malignant Hematopoiesis.

Koschade SE, Brandts CH.

J Mol Biol. 2019 Jun 28. pii: S0022-2836(19)30414-0. doi: 10.1016/j.jmb.2019.06.025. [Epub ahead of print] Review.

PMID:
31260695
5.

Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation.

Ortmann CA, Dorsheimer L, Abou-El-Ardat K, Hoffrichter J, Assmus B, Bonig H, Scholz A, Pfeifer H, Martin H, Schmid T, Brüne B, Scheich S, Steffen B, Riemann J, Hermann S, Dukat A, Bug G, Brandts CH, Wagner S, Serve H, Rieger MA.

Cell Rep. 2019 May 14;27(7):2022-2028.e3. doi: 10.1016/j.celrep.2019.04.064.

6.

Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?

von der Grün J, Rödel F, Brandts C, Fokas E, Guckenberger M, Rödel C, Balermpas P.

Cancers (Basel). 2019 Apr 3;11(4). pii: E472. doi: 10.3390/cancers11040472. Review.

7.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J.

J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9.

PMID:
30978502
8.

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.

Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S.

Nat Commun. 2019 Apr 9;10(1):1635. doi: 10.1038/s41467-019-09633-9.

9.

Conservation of structure, function and inhibitor binding in UNC-51-like kinase 1 and 2 (ULK1/2).

Chaikuad A, Koschade SE, Stolz A, Zivkovic K, Pohl C, Shaid S, Ren H, Lambert LJ, Cosford NDP, Brandts CH, Knapp S.

Biochem J. 2019 Mar 12;476(5):875-887. doi: 10.1042/BCJ20190038.

PMID:
30782972
10.

Biglycan evokes autophagy in macrophages via a novel CD44/Toll-like receptor 4 signaling axis in ischemia/reperfusion injury.

Poluzzi C, Nastase MV, Zeng-Brouwers J, Roedig H, Hsieh LT, Michaelis JB, Buhl EM, Rezende F, Manavski Y, Bleich A, Boor P, Brandes RP, Pfeilschifter J, Stelzer EHK, Münch C, Dikic I, Brandts C, Iozzo RV, Wygrecka M, Schaefer L.

Kidney Int. 2019 Mar;95(3):540-562. doi: 10.1016/j.kint.2018.10.037. Epub 2019 Jan 31.

PMID:
30712922
11.

Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy.

Ballo O, Tarazzit I, Stratmann J, Reinheimer C, Hogardt M, Wichelhaus TA, Kempf V, Serve H, Finkelmeier F, Brandts C.

PLoS One. 2019 Jan 23;14(1):e0210991. doi: 10.1371/journal.pone.0210991. eCollection 2019.

12.

Innovating the outreach of comprehensive cancer centers.

Brandts CH.

Mol Oncol. 2019 Mar;13(3):619-623. doi: 10.1002/1878-0261.12451. Epub 2019 Feb 2. Review.

13.

Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy.

Nguyen TD, Shaid S, Vakhrusheva O, Koschade SE, Klann K, Thölken M, Baker F, Zhang J, Oellerich T, Sürün D, Derlet A, Haberbosch I, Eimer S, Osiewacz HD, Behrends C, Münch C, Dikic I, Brandts CH.

Blood. 2019 Jan 10;133(2):168-179. doi: 10.1182/blood-2018-02-833475. Epub 2018 Nov 29. Erratum in: Blood. 2019 Jul 4;134(1):94.

PMID:
30498063
14.

Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis.

Bohnenberger H, Kaderali L, Ströbel P, Yepes D, Plessmann U, Dharia NV, Yao S, Heydt C, Merkelbach-Bruse S, Emmert A, Hoffmann J, Bodemeyer J, Reuter-Jessen K, Lois AM, Dröge LH, Baumeister P, Walz C, Biggemann L, Walter R, Häupl B, Comoglio F, Pan KT, Scheich S, Lenz C, Küffer S, Bremmer F, Kitz J, Sitte M, Beißbarth T, Hinterthaner M, Sebastian M, Lotz J, Schildhaus HU, Wolff H, Danner BC, Brandts C, Büttner R, Canis M, Stegmaier K, Serve H, Urlaub H, Oellerich T.

EMBO Mol Med. 2018 Sep;10(9). pii: e8428. doi: 10.15252/emmm.201708428.

15.

Biglycan is a new high-affinity ligand for CD14 in macrophages.

Roedig H, Nastase MV, Frey H, Moreth K, Zeng-Brouwers J, Poluzzi C, Hsieh LT, Brandts C, Fulda S, Wygrecka M, Schaefer L.

Matrix Biol. 2019 Apr;77:4-22. doi: 10.1016/j.matbio.2018.05.006. Epub 2018 May 17.

PMID:
29777767
16.

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.

Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, Langen KJ, Brandts C, Senft C, Harter PN, Bähr O.

Oncol Rep. 2017 Dec;38(6):3291-3296. doi: 10.3892/or.2017.6013. Epub 2017 Oct 2.

17.

SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment.

Demirel Ö, Balló O, Reddy PNG, Vakhrusheva O, Zhang J, Eichler A, Fernandes R, Badura S, Serve H, Brandts C.

PLoS One. 2017 Jul 28;12(7):e0180401. doi: 10.1371/journal.pone.0180401. eCollection 2017.

18.

Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study.

Scheich S, Reinheimer C, Brandt C, Wichelhaus TA, Hogardt M, Kempf VAJ, Brunnberg U, Brandts C, Ballo O, von Metzler I, Kessel J, Serve H, Steffen B.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1455-1462. doi: 10.1016/j.bbmt.2017.05.016. Epub 2017 May 18.

19.

Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient.

Herold S, Kuhn M, Bonin MV, Stange T, Platzbecker U, Radke J, Lange T, Sockel K, Gutsche K, Schetelig J, Röllig C, Schuster C, Roeder I, Dahl A, Mohr B, Serve H, Brandts C, Ehninger G, Bornhäuser M, Thiede C.

Leukemia. 2017 Jul;31(7):1637-1640. doi: 10.1038/leu.2017.104. Epub 2017 Mar 28. No abstract available.

PMID:
28348390
20.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.

21.

Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas.

Jennewein L, Ronellenfitsch MW, Antonietti P, Ilina EI, Jung J, Stadel D, Flohr LM, Zinke J, von Renesse J, Drott U, Baumgarten P, Braczynski AK, Penski C, Burger MC, Theurillat JP, Steinbach JP, Plate KH, Dikic I, Fulda S, Brandts C, Kögel D, Behrends C, Harter PN, Mittelbronn M.

Oncotarget. 2016 Apr 12;7(15):20016-32. doi: 10.18632/oncotarget.7910.

22.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

PMID:
26549589
23.

The Phosphatases STS1 and STS2 Regulate Hematopoietic Stem and Progenitor Cell Fitness.

Zhang J, Vakhrusheva O, Bandi SR, Demirel Ö, Kazi JU, Fernandes RG, Jakobi K, Eichler A, Rönnstrand L, Rieger MA, Carpino N, Serve H, Brandts CH.

Stem Cell Reports. 2015 Oct 13;5(4):633-46. doi: 10.1016/j.stemcr.2015.08.006. Epub 2015 Sep 10.

24.

European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies.

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO.

J Crohns Colitis. 2015 Nov;9(11):945-65. doi: 10.1093/ecco-jcc/jjv141. Epub 2015 Aug 20. No abstract available.

25.

Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 function.

Felzen V, Hiebel C, Koziollek-Drechsler I, Reißig S, Wolfrum U, Kögel D, Brandts C, Behl C, Morawe T.

Cell Death Dis. 2015 Jul 9;6:e1812. doi: 10.1038/cddis.2015.181.

26.

Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.

Wichmann C, Quagliano-Lo Coco I, Yildiz Ö, Chen-Wichmann L, Weber H, Syzonenko T, Döring C, Brendel C, Ponnusamy K, Kinner A, Brandts C, Henschler R, Grez M.

Leukemia. 2015 Feb;29(2):279-89. doi: 10.1038/leu.2014.179. Epub 2014 Jun 4.

27.

Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation.

Wolf T, Kiderlen T, Atta J, Stephan C, Kann G, Brodt HR, Brandts C.

Infection. 2014 Apr;42(2):445-7. doi: 10.1007/s15010-013-0579-8. Epub 2014 Jan 20. No abstract available.

PMID:
24442720
28.

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE.

J Clin Oncol. 2013 Sep 1;31(25):3110-8. doi: 10.1200/JCO.2012.46.4990. Epub 2013 Jul 29.

PMID:
23897964
29.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia.

N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.

30.

β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis.

Oellerich T, Oellerich MF, Engelke M, Münch S, Mohr S, Nimz M, Hsiao HH, Corso J, Zhang J, Bohnenberger H, Berg T, Rieger MA, Wienands J, Bug G, Brandts C, Urlaub H, Serve H.

Blood. 2013 May 9;121(19):3889-99, S1-66. doi: 10.1182/blood-2012-09-457887. Epub 2013 Mar 18.

PMID:
23509157
31.

Interferon-γ impairs proliferation of hematopoietic stem cells in mice.

de Bruin AM, Demirel Ö, Hooibrink B, Brandts CH, Nolte MA.

Blood. 2013 May 2;121(18):3578-85. doi: 10.1182/blood-2012-05-432906. Epub 2013 Mar 13.

PMID:
23487025
32.

FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.

Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Sartangi NF, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD.

PLoS One. 2013;8(1):e53190. doi: 10.1371/journal.pone.0053190. Epub 2013 Jan 24.

33.

Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.

Krug U, Koschmieder A, Schwammbach D, Gerss J, Tidow N, Steffen B, Bug G, Brandts CH, Schaich M, Röllig C, Thiede C, Noppeney R, Stelljes M, Büchner T, Koschmieder S, Dührsen U, Serve H, Ehninger G, Berdel WE, Müller-Tidow C.

PLoS One. 2012;7(12):e52695. doi: 10.1371/journal.pone.0052695. Epub 2012 Dec 31.

34.

A special query tool in the hospital information system to recognize patients and to increase patient numbers for clinical trials.

Koca M, Husmann G, Jesgarz J, Overath M, Brandts C, Serve H.

Stud Health Technol Inform. 2012;180:1180-1.

PMID:
22874393
35.

IT behind a platform for Translational Cancer Research - concept and objectives.

Steffens M, Husmann G, Koca M, Lablans M, Komor M, Zeissig S, Emrich K, Brandts C, Serve H, Blettner M, Uckert F.

Stud Health Technol Inform. 2012;180:1135-7.

PMID:
22874378
36.

Ubiquitination and selective autophagy.

Shaid S, Brandts CH, Serve H, Dikic I.

Cell Death Differ. 2013 Jan;20(1):21-30. doi: 10.1038/cdd.2012.72. Epub 2012 Jun 22. Review.

37.

SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control.

Reddy PN, Sargin B, Choudhary C, Stein S, Grez M, Müller-Tidow C, Berdel WE, Serve H, Brandts CH; Study Alliance Leukemia (SAL).

Blood. 2012 Aug 23;120(8):1691-702. Epub 2012 Apr 19.

PMID:
22517899
38.

Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.

Röllig C, Brandts C, Shaid S, Hentrich M, Krämer A, Junghanß C, Schleyer E, Müller-Tidow C, Berdel WE, Ritter B, Pflüger KH, Kramer M, Haibach M, Ehninger G, Serve H, Krause SW.

Leuk Lymphoma. 2012 Jun;53(6):1062-7. doi: 10.3109/10428194.2011.637210. Epub 2011 Dec 7.

PMID:
22054287
39.

Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.

Brandts CH, Schulz C, Willich N, Steffen B, Hardes J, Gosheger G, Winkelmann W, Serve H, Heinecke A, Berdel WE, Thomas M.

Cancer Chemother Pharmacol. 2012 Mar;69(3):613-20. doi: 10.1007/s00280-011-1731-8. Epub 2011 Sep 24.

PMID:
21947168
40.

Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling.

Gueller S, Hehn S, Nowak V, Gery S, Serve H, Brandts CH, Koeffler HP.

Exp Hematol. 2011 May;39(5):591-600. doi: 10.1016/j.exphem.2011.02.001. Epub 2011 Mar 1.

PMID:
21310211
41.

AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein.

Steffen B, Knop M, Bergholz U, Vakhrusheva O, Rode M, Köhler G, Henrichs MP, Bulk E, Hehn S, Stehling M, Dugas M, Bäumer N, Tschanter P, Brandts C, Koschmieder S, Berdel WE, Serve H, Stocking C, Müller-Tidow C.

Blood. 2011 Apr 21;117(16):4328-37. doi: 10.1182/blood-2009-09-242545. Epub 2011 Jan 18.

PMID:
21245488
42.

Adaptor protein Lnk inhibits c-Fms-mediated macrophage function.

Gueller S, Goodridge HS, Niebuhr B, Xing H, Koren-Michowitz M, Serve H, Underhill DM, Brandts CH, Koeffler HP.

J Leukoc Biol. 2010 Oct;88(4):699-706. doi: 10.1189/jlb.0309185. Epub 2010 Jun 22.

43.

Hemolysis is associated with low reticulocyte production index and predicts blood transfusion in severe malarial anemia.

Fendel R, Brandts C, Rudat A, Kreidenweiss A, Steur C, Appelmann I, Ruehe B, Schröder P, Berdel WE, Kremsner PG, Mordmüller B.

PLoS One. 2010 Apr 6;5(4):e10038. doi: 10.1371/journal.pone.0010038.

44.

Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.

Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Böhmer FD, Gerke V, Schmidt-Arras DE, Berdel WE, Müller-Tidow C, Mann M, Serve H.

Mol Cell. 2009 Oct 23;36(2):326-39. doi: 10.1016/j.molcel.2009.09.019.

45.

E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.

Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, Köhler G, Duyster J, Berdel WE, Müller-Tidow C, Serve H, Sargin B; Study Alliance Leukemias.

Blood. 2009 Nov 5;114(19):4197-208. doi: 10.1182/blood-2008-12-190934. Epub 2009 Sep 4.

PMID:
19734451
46.

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, Kreil S, Jones A, Score J, Metzgeroth G, Oscier D, Hall A, Brandts C, Serve H, Reiter A, Chase AJ, Cross NC.

Blood. 2009 Jun 11;113(24):6182-92. doi: 10.1182/blood-2008-12-194548. Epub 2009 Apr 22.

PMID:
19387008
47.

Flt3-dependent transformation by inactivating c-Cbl mutations in AML.

Sargin B, Choudhary C, Crosetto N, Schmidt MHH, Grundler R, Rensinghoff M, Thiessen C, Tickenbrock L, Schwäble J, Brandts C, August B, Koschmieder S, Bandi SR, Duyster J, Berdel WE, Müller-Tidow C, Dikic I, Serve H.

Blood. 2007 Aug 1;110(3):1004-12. Epub 2007 Apr 19.

PMID:
17446348
48.

Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B, Ueker A, Böhmer FD, Berdel WE, Müller-Tidow C, Serve H.

Blood. 2007 Jul 1;110(1):370-4. Epub 2007 Mar 13.

PMID:
17356133
49.

New method to quantify erythrophagocytosis by autologous monocytes.

Fendel R, Mordmüller B, Kreidenweiss A, Rudat A, Steur C, Ambrosch C, Kirstein M, Berdel WE, Kremsner PG, Brandts C.

Cytometry A. 2007 Apr;71(4):258-64.

50.

Oncogenic signaling in acute myeloid leukemia.

Brandts CH, Berdel WE, Serve H.

Curr Drug Targets. 2007 Feb;8(2):237-46. Review.

PMID:
17305501

Supplemental Content

Loading ...
Support Center